Teva Pharmaceutical Industries Receivables 2010-2024 | TEVA

Teva Pharmaceutical Industries receivables for the quarter ending September 30, 2024 were $3.462B, a 2.27% increase year-over-year.

  • Teva Pharmaceutical Industries receivables for 2023 were $3.408B, a 7.79% decline from 2022.
  • Teva Pharmaceutical Industries receivables for 2022 were $3.696B, a 18.39% decline from 2021.
  • Teva Pharmaceutical Industries receivables for 2021 were $4.529B, a 1.14% decline from 2020.

Teva Pharmaceutical Industries Receivables 2010-2024 | TEVA

  • Teva Pharmaceutical Industries receivables for 2023 were $3.408B, a 7.79% decline from 2022.
  • Teva Pharmaceutical Industries receivables for 2022 were $3.696B, a 18.39% decline from 2021.
  • Teva Pharmaceutical Industries receivables for 2021 were $4.529B, a 1.14% decline from 2020.
Related Stocks
Company NameMarket
Cap
Dr Reddy's Laboratories (RDY)$12B
BridgeBio Pharma (BBIO)$4.3B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.1B
Supernus Pharmaceuticals (SUPN)$2B
Taysha Gene Therapies (TSHA)$434M
Personalis (PSNL)$261M
Assembly Biosciences (ASMB)$98M
Sol-Gel Technologies (SLGL)$12M
Evoke Pharma (EVOK)$7M
Teligent (TLGT)$0M